|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 11 (June 1), 1999:
pp. 3637-3642
Prognostic Factors in Primary Cutaneous Lymphomas Other Than Mycosis
Fungoides and the Sézary Syndrome
F. Grange,
G. Hedelin,
P. Joly,
M. Beylot-Barry,
M. D'Incan,
M. Delaunay,
L. Vaillant,
M.F. Avril,
J. Bosq,
J. Wechsler,
S. Dalac,
C. Grosieux,
N. Franck,
E. Esteve,
C. Michel,
C. Bodemer,
B. Vergier,
L. Laroche, and
M. Bagot for the French Study Group on Cutaneous
Lymphomas (FSGCL)
From the Service de Dermatologie, Hôpital Pasteur, Colmar;
Département d'Epidémiologie et de Santé Publique,
Université Louis Pasteur, Strasbourg; Clinique Dermatologique,
Hôpital Charles Nicolle, Rouen, Institut National de la Sante et
de la Recherche Medicale (INSERM) Unite 519; Service de Dermatologie,
Hôpital du Haut Lévêque, Pessac; Service de
Dermatologie, Hôtel Dieu, Clermont-Ferrand; Unité de
Dermatologie-Cancérologie, Hôpital Pellegrin, Bordeaux;
Service de Dermatologie, Hôpital Trousseau, Tours; Service de
Dermatologie, Institut Gustave Roussy, Villejuif; Département
d'Histopathologie, Institut Gustave Roussy, Villejuif; Department de
Pathologie, Hôpital Henri-Mondor, Créteil; Service de
Dermatologie, Hôpital du Bocage, Dijon; Service de Dermatologie,
Hôpital Robert Debré, Reims; Service de Dermatologie,
Hôpital Tarnier, Paris; Service de Dermatologie, Hôpital
Porte Madeleine, Orléans; Service de Dermatologie,
Hôpital du Moenschberg, Mulhouse; Service de Dermatologie,
Hôpital Necker, Paris; Service d'Anatomie Pathologique,
Hôpital du Haut Lévêque, Pessac; Service de
Dermatologie, Hôpital Avicenne, Bobigny; and Service de
Dermatologie, Hôpital Henri-Mondor, Créteil, France.
Prognostic studies of primary cutaneous lymphomas (PCL) other than
mycosis fungoides (MF) and the Sézary syndrome (SS; non-MF/SS PCL) have been mainly performed on subgroups or on small numbers of
patients by using univariate analyses. Our aim was to identify independent prognostic factors in a large series of patients with non-MF/SS PCL. We evaluated 158 patients who were registered in the
French Study Group on Cutaneous Lymphomas database from January 1, 1986 to March 1, 1997. Variables analyzed for prognostic value were: age;
sex; type of clinical lesions; maximum diameter, location, and number
of skin lesions; cutaneous distribution (ie, local, regional, or
generalized); prognostic group according to the European Organization
for Research and Treatment of Cancer (EORTC) classification for PCL; B-
or T-cell phenotype; serum lactate dehydrogenase (LDH) level; and B
symptoms. Univariate and multivariate analyses were performed using a
model of relative survival. Forty-nine patients (31%) died. The median
relative survival time was 81 months. In univariate analysis, EORTC
prognostic group, serum LDH level, B symptoms, and variables related to
tumor extension (ie, distribution, maximum diameter, and number of skin
lesions) were significantly associated with survival. When these
variables were considered together in a multivariate analysis, EORTC
prognostic group and distribution of skin lesions remained
statistically significant, independent prognostic factors. This study
confirms the good predictive value of the EORTC classification for PCL
and shows that the distribution of skin lesions at initial evaluation
is an important prognostic indicator.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Garcia-Herrera, L. Colomo, M. Camos, J. Carreras, O. Balague, A. Martinez, A. Lopez-Guillermo, T. Estrach, and E. Campo
Primary Cutaneous Small/Medium CD4+ T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome
J. Clin. Oncol.,
July 10, 2008;
26(20):
3364 - 3371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grange, M. Beylot-Barry, P. Courville, E. Maubec, M. Bagot, B. Vergier, P. Souteyrand, L. Machet, S. Dalac, E. Esteve, et al.
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Clinicopathologic Features and Prognostic Analysis in 60 Cases
Arch Dermatol,
September 1, 2007;
143(9):
1144 - 1150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. H. Kim, R. Willemze, N. Pimpinelli, S. Whittaker, E. A. Olsen, A. Ranki, R. Dummer, R. T. Hoppe, and for the ISCL and the EORTC
TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)
Blood,
July 15, 2007;
110(2):
479 - 484.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. D. Wilson and B. D. Smith
Primary Cutaneous B-Cell Lymphoma
J. Clin. Oncol.,
August 20, 2006;
24(24):
4041 - 4041.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, P. Quaglino, N. Pimpinelli, E. Berti, G. Baliva, S. Rupoli, M. Martelli, M. Alaibac, G. Borroni, S. Chimenti, et al.
In Reply
J. Clin. Oncol.,
August 20, 2006;
24(24):
4041a - 4042.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. L. Zinzani, P. Quaglino, N. Pimpinelli, E. Berti, G. Baliva, S. Rupoli, M. Martelli, M. Alaibac, G. Borroni, S. Chimenti, et al.
Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas
J. Clin. Oncol.,
March 20, 2006;
24(9):
1376 - 1382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Willemze, E. S. Jaffe, G. Burg, L. Cerroni, E. Berti, S. H. Swerdlow, E. Ralfkiaer, S. Chimenti, J. L. Diaz-Perez, L. M. Duncan, et al.
WHO-EORTC classification for cutaneous lymphomas
Blood,
May 15, 2005;
105(10):
3768 - 3785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grange, T. Petrella, M. Beylot-Barry, P. Joly, M. D'Incan, M. Delaunay, L. Machet, M.-F. Avril, S. Dalac, P. Bernard, et al.
Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas
Blood,
May 15, 2004;
103(10):
3662 - 3668.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Bekkenk, M. H. Vermeer, P. M. Jansen, A. M. W. van Marion, M. R. Canninga-van Dijk, P. M. Kluin, M.-L. Geerts, C. J. L. M. Meijer, and R. Willemze
Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients
Blood,
September 15, 2003;
102(6):
2213 - 2219.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Fink-Puches, P. Zenahlik, B. Back, J. Smolle, H. Kerl, and L. Cerroni
Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients
Blood,
February 1, 2002;
99(3):
800 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Connors, E. D. Hsi, and F. M. Foss
Lymphoma of the Skin
Hematology,
January 1, 2002;
2002(1):
263 - 282.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. Grange, M. W. Bekkenk, J. Wechsler, C. J.L.M. Meijer, L. Cerroni, M. Bernengo, J. Bosq, G. Hedelin, R. Fink Puches, W. A. van Vloten, et al.
Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study
J. Clin. Oncol.,
August 15, 2001;
19(16):
3602 - 3610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Sarris, I. Braunschweig, L. J. Medeiros, M. Duvic, C. S. Ha, M. A. Rodriguez, F. B. Hagemeister, P. McLaughlin, J. Romaguera, J. Cox, et al.
Primary Cutaneous Non-Hodgkin's Lymphoma of Ann Arbor Stage I: Preferential Cutaneous Relapses but High Cure Rate With Doxorubicin-Based Therapy
J. Clin. Oncol.,
January 15, 2001;
19(2):
398 - 405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Vergier, A. de Muret, M. Beylot-Barry, L. Vaillant, D. Ekouevi, G. Chene, A. Carlotti, N. Franck, P. Dechelotte, P. Souteyrand, et al.
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases
Blood,
April 1, 2000;
95(7):
2212 - 2218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. W. Bekkenk, M. H. Vermeer, M.-L. Geerts, E. M. Noordijk, F. Heule, P. C. van Voorst Vader, W. A. van Vloten, C. J.L.M. Meijer, and R. Willemze
Treatment of Multifocal Primary Cutaneous B-Cell Lymphoma: A Clinical Follow-Up Study of 29 Patients
J. Clin. Oncol.,
August 1, 1999;
17(8):
2471 - 2471.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
